Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
50.91-0.17 (-0.33%)
At close: 04:03PM EST
50.63 -0.28 (-0.55%)
After hours: 07:57PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close51.08
Open50.56
Bid50.63 x 800
Ask50.91 x 4000
Day's Range50.48 - 51.33
52 Week Range41.45 - 61.71
Volume15,858,877
Avg. Volume20,140,077
Market Cap285.751B
Beta (5Y Monthly)0.64
PE Ratio (TTM)29.82
EPS (TTM)1.71
Earnings DateFeb 06, 2023 - Feb 10, 2023
Forward Dividend & Yield1.60 (3.51%)
Ex-Dividend DateNov 03, 2022
1y Target EstN/A
  • Insider Monkey

    10 Biggest Issues In the World and The Companies Working on Solving Them

    In this article, we take a look at the 10 biggest issues in the world and the companies working on solving them. You can skip our detailed analysis of the plight of the world and go directly to 5 Biggest Issues in the World and The Companies Working on Solving Them. The world is currently […]

  • Motley Fool

    Why Shares of Prometheus Biosciences Slumped This Week

    Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.

  • Zacks

    Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

    Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.

Advertisement
Advertisement